Mark Neumann
Net Worth

Last updated:

What is Mark Neumann net worth?

The estimated net worth of Mr. Mark Neumann is at least $29,151,961 as of 16 Aug 2024. He owns shares worth $3,916,539 as insider, has earned $19,395,622 from insider trading and has received compensation worth at least $5,839,800 in Intra-Cellular Therapies, Inc..

What is the salary of Mark Neumann?

Mr. Mark Neumann salary is $973,300 per year as EVice President & Chief Commercial Officer in Intra-Cellular Therapies, Inc..

How old is Mark Neumann?

Mr. Mark Neumann is 62 years old, born in 1963.

What stocks does Mark Neumann currently own?

As insider, Mr. Mark Neumann owns shares in one company:

Company Title Shares Price per share Total value
Intra-Cellular Therapies, Inc. (ITCI) EVice President & Chief Commercial Officer 29,700 $131.87 $3,916,539

What does Intra-Cellular Therapies, Inc. do?

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI logo
ITCI
Intra-Cellular Therapies, Inc.
$131.87

Mark Neumann insider trading

Intra-Cellular Therapies, Inc.

Mr. Mark Neumann has made 43 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 86,348 units of ITCI stock on 8 Apr 2022. As of 16 Aug 2024 he still owns at least 29,700 units of ITCI stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (right to buy) 18,714 $36.89 $690,359
Sale
Common Stock 18,714 $75.08 $1,405,047
Option
Common Stock 18,714 $36.89 $690,359
Sale
Common Stock 1,313 $66.86 $87,787
Sale
Common Stock 1,729 $65.92 $113,976
Sale
Common Stock 4,303 $65.11 $280,168
Option
Restricted Stock Units 7,345 N/A N/A
Option
Common Stock 7,345 N/A N/A
Sale
Common Stock 4,496 $66.95 $301,007
Sale
Common Stock 8,636 $66.37 $573,171
Option
Restricted Stock Units 13,132 N/A N/A
Option
Common Stock 13,132 N/A N/A
Sale
Common Stock 200 $68.03 $13,606
Option
Common Stock 7,907 N/A N/A
Sale
Common Stock 6,904 $67.49 $465,951
Sale
Common Stock 4,956 $66.67 $330,417
Option
Stock Option (right to buy) 26,754 $23.94 $640,491
Sale
Common Stock 15,639 $55.02 $860,411
Option
Common Stock 26,754 $23.94 $640,491
Sale
Common Stock 26,754 $55.98 $1,497,742
Option
Common Stock 55,300 $18.59 $1,028,027
Sale
Common Stock 55,300 $58.79 $3,251,087
Option
Stock Option (right to buy) 55,300 $18.59 $1,028,027
Sale
Common Stock 10,183 $54.01 $549,984
Sale
Common Stock 5,421 $54.86 $297,396
Sale
Common Stock 423 $44.05 $18,633
Sale
Common Stock 3,335 $45.1 $150,409
Option
Restricted Stock Units 7,344 N/A N/A
Sale
Common Stock 1,800 $42.74 $76,932
Option
Common Stock 7,344 N/A N/A
Sale
Common Stock 6,750 $43.5 $293,625
Sale
Common Stock 7,241 $50.01 $362,122
Sale
Common Stock 4,046 $47.12 $190,648
Option
Restricted Stock Units 7,906 N/A N/A
Option
Common Stock 7,906 N/A N/A
Sale
Common Stock 3,140 $46.61 $146,355
Sale
Common Stock 123 $47.32 $5,820
Sale
Common Stock 635 $48.93 $31,071
Option
Restricted Stock Units 11,139 N/A N/A
Option
Common Stock 11,139 N/A N/A
Sale
Common Stock 17,476 $63.55 $1,110,600
Option
Stock Option (right to buy) 86,348 $12.73 $1,099,210
Option
Common Stock 86,348 $12.73 $1,099,210
Sale
Common Stock 14,885 $65.14 $969,609
Sale
Common Stock 53,987 $64.42 $3,477,843
Sale
Common Stock 1,371 $51.33 $70,373
Option
Restricted Stock Units 7,906 N/A N/A
Sale
Common Stock 2,660 $52.94 $140,820
Sale
Common Stock 3,875 $52.03 $201,616
Option
Common Stock 7,906 N/A N/A
Sale
Common Stock 4,607 $54.84 $252,648
Sale
Common Stock 6,532 $55.6 $363,179
Option
Restricted Stock Units 11,139 N/A N/A
Option
Common Stock 11,139 N/A N/A
Sale
Common Stock 2,761 $41.74 $115,244
Sale
Common Stock 4,252 $40.09 $170,463
Sale
Common Stock 13,935 $40.8 $568,548
Option
Restricted Stock Units 20,948 N/A N/A
Option
Common Stock 20,948 N/A N/A
Sale
Common Stock 500 $38.88 $19,440
Sale
Common Stock 1,958 $39.44 $77,224
Option
Restricted Stock Units 13,448 N/A N/A
Sale
Common Stock 4,288 $40.77 $174,822
Sale
Common Stock 6,702 $41.49 $278,066
Sale
Common Stock 5,184 $19.63 $101,762
Sale
Common Stock 5,184 N/A N/A
Option
Restricted Stock Units 11,139 N/A N/A
Option
Common Stock 11,139 N/A N/A
Sale
Common Stock 9,684 N/A N/A
Option
Restricted Stock Units 20,948 N/A N/A
Option
Common Stock 20,948 N/A N/A
Sale
Common Stock 6,792 N/A N/A
Option
Common Stock 13,448 N/A N/A
Option
Restricted Stock Units 13,448 N/A N/A
Option
Common Stock 20,947 N/A N/A
Option
Restricted Stock Units 20,947 N/A N/A
Sale
Common Stock 6,774 N/A N/A
Option
Common stock 13,448 N/A N/A
Option
Restricted Stock Units 13,448 N/A N/A

Intra-Cellular Therapies key executives

Intra-Cellular Therapies, Inc. executives and other stock owners filed with the SEC: